What are the key products being discussed in this filing?

The key products discussed are ZETIA (ezetimibe) and VYTORIN (ezetimibe with simvastatin).

What is the main takeaway from the new study results for VYTORIN?

The new study results indicate that VYTORIN provided significantly greater reductions in LDL cholesterol compared to competitor products like Lipitor and Zocor across different dosing ranges.

What was the outcome of adding ZETIA to existing statin therapy?

A community-based trial involving over 3,000 patients showed that adding ZETIA to statin therapy produced significant reductions in LDL-cholesterol.

Where can investors find more information about these products and study results?

Investors can find more information in the press releases and the FAQ document attached as exhibits to this 8-K filing, and also on the Schering-Plough website at www.schering-plough.com.

MRK 8-K SEC Disclosure — Mar 15, 2004

Summary

This Merck & Co., Inc. (MRK) 8-K filing from March 15, 2004, primarily serves to disclose information related to the products ZETIA and VYTORIN through attached press releases and an FAQ document. The company is highlighting new study results that demonstrate the efficacy of ezetimibe with simvastatin (VYTORIN) in significantly reducing LDL cholesterol compared to existing treatments like Lipitor and Zocor across various dosing ranges. Additionally, a community-based trial showed that adding ZETIA to statin therapy yielded substantial reductions in LDL-cholesterol.

Key Highlights

1Disclosure of new study results for ezetimibe with simvastatin (VYTORIN) showing superior LDL cholesterol reduction compared to Lipitor and Zocor.
2Announcement of positive trial results for adding ZETIA to statin therapy, demonstrating significant LDL cholesterol reductions.
3The filing includes press releases dated March 8, 2004, and March 10, 2004, detailing these findings.
4An Investor Frequently Asked Questions and Answers document (dated March 15, 2004) is also provided to address potential investor queries.
5The exhibits focus on the performance and benefits of Merck's cholesterol-lowering product portfolio, specifically ZETIA and VYTORIN.
6Information related to these products is also available on the Schering-Plough website.